Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis

dc.creatorBrenda Fernanda Moreira Castro
dc.creatorSilvia Ligório Fialho
dc.creatorCarolina Nunes da Silva
dc.creatorLidia Pereira Barbosa Cordeiro
dc.creatorSarah Pereira de Freitas Cenachi
dc.creatorDaniel Vítor de Vasconcelos Santos
dc.creatorRenes Resende Machado
dc.creatorLuiz Guilherme Dias Heneine
dc.creatorLuciana Maria Silva
dc.creatorArmando Silva-Cunha
dc.date.accessioned2023-12-05T20:34:25Z
dc.date.accessioned2025-09-09T01:02:06Z
dc.date.available2023-12-05T20:34:25Z
dc.date.issued2022
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1016/j.crphar.2022.100107
dc.identifier.issn2590-2571
dc.identifier.urihttps://hdl.handle.net/1843/61740
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofCurrent Research in Pharmacology and Drug Discovery
dc.rightsAcesso Aberto
dc.subjectMeliteno
dc.subjectPeptídeos
dc.subjectInflamação
dc.subjectUveíte
dc.subjectOlho
dc.subject.otherMelittin
dc.subject.otherPeptide
dc.subject.otherInflammation
dc.subject.otherUveitis
dc.subject.otherAntiangiogenic
dc.subject.otherEye
dc.titleLow-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis
dc.typeArtigo de periódico
local.citation.epage15
local.citation.issue2022
local.citation.spage100107
local.citation.volume3
local.description.resumoUveitis is a group of sight-threatening ocular inflammatory disorders, whose mainstay of therapy is associated with severe adverse events, prompting the investigation of alternative treatments. The peptide melittin (MEL) is the major component of Apis mellifera bee venom and presents anti-inflammatory and antiangiogenic activities, with possible application in ophthalmology. This work aims to investigate the potential of intravitreal MEL in the treatment of ocular diseases involving inflammatory processes, especially uveitis. Safety of MEL was assessed in retinal cells, chick embryo chorioallantoic membranes, and rats. MEL at concentrations safe for intravitreal administration showed an antiangiogenic activity in the chorioallantoic membrane model comparable to bevacizumab, used as positive control. A protective anti-inflammatory effect in retinal cells stimulated with lipopolysaccharide (LPS) was also observed, without toxic effects. Finally, rats with bacille Calmette-Guerin- (BCG) induced uveitis treated with intravitreal MEL showed attenuated disease progression and improvement of clinical, morphological, and functional parameters, in addition to decreased levels of proinflammatory mediators in the posterior segment of the eye. These effects were comparable to the response observed with corticosteroid treatment. Therefore, MEL presents adequate safety profile for intraocular administration and has therapeutic potential as an anti-inflammatory and antiangiogenic agent for ocular diseases.
local.publisher.countryBrasil
local.publisher.departmentFAR - DEPARTAMENTO DE PRODUTOS FARMACÊUTICOS
local.publisher.departmentFARMACIA - FACULDADE DE FARMACIA
local.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S259025712200027X?via%3Dihub

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
Low-dose melittin is safe for intravitreal administration and ameliorates inflammation in an experimental model of uveitis.pdf
Tamanho:
4.34 MB
Formato:
Adobe Portable Document Format

Licença do pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição: